Back to Search Start Over

Ectopic expression of a combination of 5 genes detects high risk forms of T-cell acute lymphoblastic leukemia.

Authors :
Peng LJ
Zhou YB
Geng M
Bourova-Flin E
Chuffart F
Zhang WN
Wang T
Gao MQ
Xi MP
Cheng ZY
Zhang JJ
Liu YF
Chen B
Khochbin S
Wang J
Rousseaux S
Mi JQ
Source :
BMC genomics [BMC Genomics] 2022 Jun 24; Vol. 23 (1), pp. 467. Date of Electronic Publication: 2022 Jun 24.
Publication Year :
2022

Abstract

Background: T cell acute lymphoblastic leukemia (T-ALL) defines a group of hematological malignancies with heterogeneous aggressiveness and highly variable outcome, making therapeutic decisions a challenging task. We tried to discover new predictive model for T-ALL before treatment by using a specific pipeline designed to discover aberrantly active gene.<br />Results: The expression of 18 genes was significantly associated with shorter survival, including ACTRT2, GOT1L1, SPATA45, TOPAZ1 and ZPBP (5-GEC), which were used as a basis to design a prognostic classifier for T-ALL patients. The molecular characterization of the 5-GEC positive T-ALL unveiled specific characteristics inherent to the most aggressive T leukemic cells, including a drastic shut-down of genes located on the mitochondrial genome and an upregulation of histone genes, the latter characterizing high risk forms in adult patients. These cases fail to respond to the induction treatment, since 5-GEC either predicted positive minimal residual disease (MRD) or a short-term relapse in MRD negative patients.<br />Conclusion: Overall, our investigations led to the discovery of a homogenous group of leukemic cells with profound alterations of their biology. It also resulted in an accurate predictive tool that could significantly improve the management of T-ALL patients.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
1471-2164
Volume :
23
Issue :
1
Database :
MEDLINE
Journal :
BMC genomics
Publication Type :
Academic Journal
Accession number :
35751016
Full Text :
https://doi.org/10.1186/s12864-022-08688-1